Immune System

Allergic rhinitis: outpatient management

Clinical Overview and When to Suspect Allergic Rhinitis

— Peak onset late childhood to early adulthood; often improves but rarely fully resolves in older age

— Strong familial clustering; part of the atopic march (atopic dermatitis → food allergy → asthma → allergic rhinitis)

— Intermittent: <4 days/week OR <4 weeks/year

— Persistent: ≥4 days/week AND ≥4 weeks/year

— Severity: mild (no impairment of sleep, school, work, daily activities) vs moderate–severe (any impairment)

— Postnasal drip, throat clearing, chronic cough, ear fullness, snoring

— Worsening of comorbid asthma control during allergy season is a major clue

Board pearl: A patient with "recurrent sinus infections" on multiple antibiotic courses who actually has persistent allergic rhinitis with congestion is a classic Step 3 stem — the right answer is intranasal corticosteroid, not another antibiotic course.

Definition: IgE-mediated inflammation of the nasal mucosa triggered by inhaled allergens, with mast cell degranulation releasing histamine, leukotrienes, and tryptase

Epidemiology: Affects ~20–30% of US adults and up to 40% of children; one of the most common chronic conditions seen in primary care

Classification (ARIA):

When to suspect: Recurrent or chronic sneezing, rhinorrhea, nasal pruritus, nasal congestion, and itchy watery eyes, especially seasonal pattern or with known triggers (pollen, dust mite, animal dander, mold)

High-yield comorbidities: Asthma (40–80% overlap), atopic dermatitis, allergic conjunctivitis, chronic rhinosinusitis with nasal polyps, otitis media with effusion, obstructive sleep apnea

Functional impact: Decreased sleep quality, daytime fatigue, impaired school/work productivity, reduced quality of life — Step 3 questions emphasize functional outcomes to justify stepping up therapy

Cost-of-care angle: Allergic rhinitis is a leading driver of missed workdays and ambulatory visits; appropriate stepped therapy reduces ED visits for asthma exacerbations

Presentation Patterns and Key History

— Add ocular symptoms (itching, tearing, redness) → strongly suggests allergic etiology over vasomotor or infectious rhinitis

— Itch is the single most discriminating symptom for allergic vs non-allergic rhinitis

— Seasonal: spring (tree pollen), late spring/summer (grass), late summer/fall (ragweed, weeds)

— Perennial: dust mites, cockroach, pet dander, indoor molds — symptoms year-round, worse in bedroom/morning

— Episodic: symptoms only with specific exposure (visiting a home with cats)

— Onset, duration, seasonality, geographic triggers, indoor vs outdoor worsening

— Home environment: carpeting, pets, pillows, humidity, visible mold, smoking exposure

— Occupational exposures: bakers (flour), healthcare (latex), woodworkers, lab animal handlers — occupational rhinitis is reportable in some states

— Response to prior OTC antihistamines or intranasal sprays

— Family history of atopy

— Unilateral symptoms → foreign body, tumor, CSF leak, polyp

— Bloody discharge → granulomatosis with polyangiitis, neoplasm, cocaine use

— Anosmia disproportionate to congestion → nasal polyps, COVID, neurodegenerative

— Facial pain, fever, purulent drainage → rhinosinusitis

— Systemic symptoms (weight loss, arthralgias) → vasculitis

Step 3 management: When a patient says "the OTC loratadine didn't work," clarify whether they took it daily for ≥2 weeks, not as-needed — episodic dosing is a common reason for "treatment failure" and reframes management before escalating.

Core symptom tetrad: sneezing, rhinorrhea (clear), nasal pruritus, nasal congestion

Temporal pattern:

Targeted history questions:

Red flags requiring workup beyond allergic rhinitis:

Quality-of-life screening: Ask about sleep disturbance, daytime somnolence, school/work absences, mood, and impact on asthma control — drives therapy intensity

Physical Exam Findings

— Allergic shiners: dark infraorbital discoloration from venous congestion

— Dennie-Morgan lines: prominent infraorbital skin folds

— Allergic salute: transverse nasal crease from chronic upward rubbing (especially children)

— Mouth breathing, open-mouth posture, "adenoid facies" in chronic pediatric cases

— Pale, boggy, bluish-gray turbinates with clear watery secretions — classic allergic pattern

— Erythematous turbinates with purulent discharge suggest infectious rhinitis

— Cobblestoning of posterior pharynx from chronic postnasal drip

— Inspect for nasal polyps: pale, grape-like, insensate masses — if present, screen for asthma, aspirin sensitivity (AERD), and cystic fibrosis in children

— Septal deviation, perforation (cocaine, intranasal steroid misuse, GPA), or ulceration

Key distinction: Allergic rhinitis = pale, boggy, blue-gray turbinates with clear discharge. Viral rhinitis = erythematous turbinates with clear-to-mucoid discharge plus systemic symptoms. Bacterial sinusitis = erythematous mucosa with purulent discharge, facial tenderness, often after 10+ days of viral symptoms. Recognizing the mucosal color pattern is a frequent Step 3 image-stem differentiator.

General appearance clues:

Nasal exam (anterior rhinoscopy with otoscope or speculum):

Ocular exam: Conjunctival injection, chemosis, watery discharge, periorbital edema; rule out keratitis

Ear exam: Retracted or dull tympanic membrane, air-fluid level — eustachian tube dysfunction or serous otitis media

Pulmonary exam: Always auscultate — wheeze suggests concurrent asthma; 80% of asthmatics have allergic rhinitis and treating rhinitis improves asthma control

Skin: Look for atopic dermatitis flexural involvement, xerosis, urticaria

Vital signs: Should be normal — fever or tachycardia points away from uncomplicated allergic rhinitis toward infection or systemic disease

Diagnostic Workup — Initial Evaluation

— Symptoms refractory to appropriate stepped therapy

— Need to identify specific allergens for environmental control

— Considering allergen immunotherapy (subcutaneous or sublingual)

— Diagnostic uncertainty (overlap with non-allergic rhinitis, vasomotor)

— Pre-occupational assessment

— Skin prick testing (SPT): gold standard, performed by allergist; results in 15–20 minutes; more sensitive and cost-effective; requires holding antihistamines 5–7 days

— Serum specific IgE (ImmunoCAP): useful when antihistamines cannot be stopped, severe dermatographism, extensive eczema, history of anaphylaxis, or patient on beta-blocker; no need to hold medications

— CT sinus only if chronic rhinosinusitis, polyps, or complications suspected

— MRI for suspected mass or intracranial extension

Board pearl: Hold H1 antihistamines for 5–7 days before skin prick testing — failure to hold causes false negatives. Tricyclic antidepressants and some antipsychotics (H1 activity) should be held 7–14 days. Topical and intranasal corticosteroids do not need to be stopped.

Allergic rhinitis is a clinical diagnosis in most outpatient cases — testing is reserved for diagnostic uncertainty, treatment failure, or planning immunotherapy

No routine labs needed for uncomplicated cases responding to empiric therapy

When to test:

Specific IgE testing — two options:

Total IgE: Not useful for diagnosis of allergic rhinitis — nonspecific, often elevated in many atopic and non-atopic conditions

CBC with eosinophil count: Not required; mild peripheral eosinophilia may support atopy but is neither sensitive nor specific

Nasal smear for eosinophils: Historical; rarely used today but can distinguish allergic (eosinophils) from NARES (nonallergic rhinitis with eosinophilia) — both treated similarly with intranasal corticosteroids

Imaging: Not indicated routinely

Diagnostic Workup — Advanced or Confirmatory Studies

— Useful when SPT shows multiple positives without clear clinical correlation

— Helps decide candidacy and content of immunotherapy

— Example: distinguishing primary peanut sensitization (Ara h 2) from pollen cross-reactivity

— Reserved for occupational rhinitis evaluation or research

— Confirms clinical relevance when SPT/IgE results discordant with history

— Suspect when history strongly suggests allergy but systemic testing negative

— Diagnose by nasal allergen provocation; refer to allergist

— Refractory symptoms, suspected polyps, anatomic obstruction, unilateral disease, epistaxis

— Performed by ENT

— Avoid routine ordering — most allergic rhinitis CTs show only mucosal thickening that does not change management

Step 3 management: A 32-year-old baker with workday-only sneezing and rhinorrhea that resolves on weekends and vacation — order specific IgE to flour antigens (alpha-amylase, wheat) and consider occupational medicine referral. Document for workers' compensation and OSHA reporting.

Component-resolved diagnostics (CRD): Molecular allergen testing that distinguishes major sensitizing proteins from cross-reactive ones

Nasal provocation testing: Direct application of allergen to nasal mucosa with symptom scoring and acoustic rhinometry

Local allergic rhinitis (LAR): Patients with classic symptoms but negative SPT and serum IgE; have localized nasal IgE production

Fiberoptic nasal endoscopy: For evaluation of:

CT sinus (non-contrast, thin cuts): When chronic rhinosinusitis (>12 weeks symptoms), polyps, anatomic anomaly, or pre-surgical planning is needed

Pulmonary function testing: Order spirometry with bronchodilator in any allergic rhinitis patient with cough, wheeze, exercise intolerance, or nocturnal symptoms — high rate of undiagnosed asthma

Workup for mimics: ANCA (suspected GPA), sweat chloride/CFTR (pediatric polyps), urine drug screen (cocaine if septal perforation)

Risk Stratification and Stepped Management Logic

— Dust mite: allergen-impermeable mattress/pillow encasings, wash bedding weekly in hot water (≥130°F), reduce humidity <50%, HEPA filter

— Pollen: keep windows closed during peak season, shower after outdoor exposure, check daily pollen counts

— Pet dander: ideally remove pet; if not, restrict from bedroom, HEPA filter, weekly pet bathing

— Mold: fix leaks, dehumidify, clean visible mold with diluted bleach

— Smoking cessation (active and secondhand) — major irritant amplifier

— Second-generation oral H1 antihistamine (loratadine, cetirizine, fexofenadine, levocetirizine) PRN

— OR intranasal antihistamine (azelastine) PRN

— Intranasal corticosteroid (INCS) daily — most effective single agent; first-line for moderate–severe or persistent disease

— Examples: fluticasone, mometasone, triamcinolone, budesonide (all OTC)

— Counsel: full effect requires 2 weeks of daily use; proper technique (spray away from septum, head slightly forward, "sniff gently")

— Add intranasal antihistamine (azelastine) — combination products (azelastine/fluticasone) preferred over INCS + oral antihistamine for refractory disease

— Reassess adherence and spray technique first

Board pearl: For moderate–severe persistent allergic rhinitis, intranasal corticosteroid alone outperforms oral antihistamine alone and is the correct Step 3 first-line answer — even if the patient prefers a pill. The combination intranasal corticosteroid + intranasal antihistamine beats either alone in refractory cases.

ARIA stepwise approach based on classification (intermittent vs persistent) and severity (mild vs moderate–severe)

Step 1 — Environmental control + patient education (all patients):

Step 2 — Mild intermittent symptoms:

Step 3 — Persistent or moderate–severe symptoms:

Step 4 — Inadequate response to INCS monotherapy:

Step 5 — Refractory disease: Refer to allergist for immunotherapy

Pharmacotherapy — First-Line Drug Regimens

— Fluticasone propionate 50 mcg, 1–2 sprays each nostril daily (OTC)

— Mometasone furoate 50 mcg, 2 sprays each nostril daily (OTC, approved age ≥2)

— Triamcinolone, budesonide, ciclesonide, fluticasone furoate — all comparable efficacy

— Onset: 12 hours to days; peak effect at 2–4 weeks of daily use

— Side effects: local irritation, epistaxis (10%), rare septal perforation with improper technique; minimal systemic absorption; growth velocity monitoring in children on long-term use

— Loratadine 10 mg, cetirizine 10 mg, fexofenadine 180 mg, levocetirizine 5 mg daily

— Better for sneezing, itching, rhinorrhea than congestion

— Cetirizine and levocetirizine more sedating than loratadine/fexofenadine

— Avoid first-generation (diphenhydramine, chlorpheniramine) — anticholinergic burden, sedation, Beers criteria in elderly

— Azelastine, olopatadine — rapid onset (15–30 min), effective for congestion (unlike oral antihistamines)

— Bitter taste is the main complaint

— Montelukast — second-line; FDA boxed warning (2020) for neuropsychiatric effects (depression, suicidal ideation, agitation) — reserve for patients with concurrent asthma when other agents inadequate; document risk-benefit discussion

— Oral pseudoephedrine short-term only; raises BP, contraindicated in uncontrolled HTN, CAD, hyperthyroidism, BPH

— Topical oxymetazoline ≤3 days only — rhinitis medicamentosa with prolonged use

Step 3 management: Counsel patients starting INCS that it is not a rescue spray — daily use is essential, and judging efficacy before 2 weeks leads to premature abandonment and unnecessary escalation.

Intranasal corticosteroids (INCS) — most effective single agent:

Second-generation oral antihistamines (preferred over first-gen):

Intranasal antihistamines:

Leukotriene receptor antagonists:

Intranasal anticholinergic (ipratropium): Targeted therapy for rhinorrhea-predominant symptoms (including gustatory and skier's rhinitis); no effect on congestion or sneezing

Intranasal cromolyn: Mast cell stabilizer; QID dosing limits adherence; safe in pregnancy

Decongestants:

Allergen Immunotherapy and Refractory Disease

— Moderate–severe allergic rhinitis inadequately controlled despite optimized pharmacotherapy and environmental control

— Patient preference to reduce long-term medication use

— Concurrent allergic asthma

— Documented specific IgE to clinically relevant allergens

— Build-up phase: weekly injections of increasing allergen doses for 3–6 months

— Maintenance: monthly injections for 3–5 years total

— Administered in clinic with 30-minute post-injection observation (anaphylaxis risk)

— Epinephrine and trained personnel must be available — never administer at home

— Disease-modifying: benefits persist years after discontinuation; may prevent progression to asthma in children and development of new sensitizations

— FDA-approved for grass (Timothy, 5-grass), ragweed, and dust mite

— First dose given in office; subsequent doses at home

— Prescribe epinephrine auto-injector; patient must be trained

— Local oral itching/swelling common; systemic anaphylaxis rare

— Convenient, especially for needle-averse patients and children

— Severe uncontrolled asthma (FEV1 <70% predicted)

— Beta-blocker use — blunts epinephrine response if anaphylaxis (relative contraindication; weigh risk)

— ACE inhibitors — increased risk of severe anaphylaxis (relative)

— Active autoimmune disease, malignancy, pregnancy (do not initiate, but may continue maintenance if tolerating)

— Omalizumab (anti-IgE) — off-label for allergic rhinitis; FDA-approved for chronic rhinosinusitis with nasal polyps

— Dupilumab, mepolizumab — for CRSwNP

Board pearl: Refer for immunotherapy when symptoms persist despite INCS + intranasal antihistamine combination, when patient wants to reduce chronic medication burden, or when allergic asthma coexists — it is the only disease-modifying therapy for allergic rhinitis.

Indications for allergen immunotherapy (AIT):

Subcutaneous immunotherapy (SCIT):

Sublingual immunotherapy (SLIT) tablets:

Contraindications to AIT:

Biologics for severe refractory disease:

Surgical options: Turbinate reduction, septoplasty, functional endoscopic sinus surgery for anatomic contributors

Special Populations — Elderly and Hepatic/Renal Impairment

— Avoid first-generation antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine) — Beers Criteria flag due to anticholinergic burden: confusion, urinary retention, falls, dry mouth/eyes, blurred vision, constipation, worsening BPH and narrow-angle glaucoma

— Preferred: intranasal corticosteroids (minimal systemic absorption), second-generation antihistamines (loratadine, fexofenadine favored over cetirizine for less sedation)

— Avoid oral decongestants (pseudoephedrine, phenylephrine) — exacerbate hypertension, urinary retention, insomnia, arrhythmia; especially risky with CAD, HF, BPH

— Saline nasal irrigation safe and underutilized

— Cetirizine and levocetirizine: renally cleared — reduce dose if CrCl <50 (cetirizine 5 mg daily; avoid if CrCl <10)

— Fexofenadine: renally cleared — reduce to 60 mg daily if CrCl <80

— Loratadine: primarily hepatic; reduce frequency in severe renal disease

— Intranasal medications largely unaffected by renal function

— Loratadine and desloratadine undergo CYP3A4/2D6 metabolism — use with caution in cirrhosis; consider every-other-day dosing

— Fexofenadine preferred in hepatic disease (minimal hepatic metabolism)

— Watch for additive sedation with benzodiazepines, opioids, gabapentinoids

— Pseudoephedrine + MAOI = hypertensive crisis (contraindicated)

— Montelukast: monitor for new depression/behavioral changes, especially in elderly with baseline cognitive concerns

Key distinction: In an elderly patient with new "allergic rhinitis," review the medication list first — terazosin, lisinopril, and sildenafil are common offenders causing nasal congestion that resolves with drug change, not antihistamines.

Elderly patients — key principles:

Renal impairment:

Hepatic impairment:

Polypharmacy considerations:

Differential expansion in elderly: Always consider drug-induced rhinitis (ACE inhibitors, alpha-blockers, NSAIDs, sildenafil, beta-blockers), atrophic rhinitis (dry crusted mucosa), and vasomotor rhinitis (often misdiagnosed as allergic)

Special Populations — Pregnancy and Pediatrics

— Non-pharmacologic first: saline nasal irrigation, nasal strips, head elevation at sleep, environmental control

— Pregnancy rhinitis (6+ weeks of nasal congestion in last trimester with no other allergy signs, resolves within 2 weeks postpartum) is distinct — usually managed conservatively without antiallergic drugs

— Safest pharmacotherapy:

— Intranasal corticosteroids: budesonide has the most pregnancy safety data (former Category B); generally first-line

— Second-generation antihistamines: loratadine and cetirizine preferred

— Intranasal cromolyn: safe across pregnancy

— Saline irrigation: safe and effective adjunct

— Avoid: oral decongestants in first trimester (pseudoephedrine linked to gastroschisis); montelukast generally avoided unless asthma benefit; phenylephrine vasoconstriction concerns

— Continue established immunotherapy at maintenance dose; do not initiate new immunotherapy during pregnancy

— Symptoms often masquerade as "recurrent colds," chronic cough, snoring, or behavioral/school issues from poor sleep

— Watch for adenoid facies, mouth breathing, dental malocclusion, allergic salute

— Intranasal corticosteroids approved by age:

— Mometasone, fluticasone furoate ≥ age 2

— Fluticasone propionate, triamcinolone ≥ age 2–4

— Monitor linear growth with long-term use; mometasone and fluticasone furoate have least growth effect

— Second-generation oral antihistamines: cetirizine ≥6 months, loratadine ≥2 years, fexofenadine ≥2 years

— Avoid first-generation antihistamines in children <6 — paradoxical excitation, sedation impairing learning, fatal overdoses reported

— Montelukast — boxed warning especially relevant; counsel parents about behavioral changes

— SLIT tablets approved for ages 5+ (varies by product)

Step 3 management: A 28-year-old at 14 weeks gestation with persistent allergic rhinitis — start intranasal budesonide plus saline rinses and dust mite environmental control; avoid oral decongestants; loratadine PRN is acceptable if needed.

Pregnancy management:

Pediatric management:

School/sports: Address impact on attendance, concentration, sleep quality, and athletic performance; document for school accommodation plans

Complications and Adverse Outcomes

— Chronic rhinosinusitis: persistent mucosal inflammation impairs sinus drainage; consider when symptoms >12 weeks with facial pressure, nasal obstruction, decreased smell, mucopurulent drainage

— Nasal polyposis: especially with concurrent asthma; screen for aspirin-exacerbated respiratory disease (AERD) — triad of asthma, polyps, NSAID/aspirin sensitivity

— Otitis media with effusion: eustachian tube dysfunction → conductive hearing loss → speech delay in children

— Obstructive sleep apnea worsening: nasal obstruction increases upper airway resistance

— Sleep-disordered breathing: snoring, fragmented sleep, daytime fatigue, mood and cognitive effects

— Asthma exacerbation: "one airway" concept — uncontrolled allergic rhinitis is the strongest modifiable risk factor for poor asthma control

— Allergic conjunctivitis: chronic eye rubbing → keratoconus risk

— Rhinitis medicamentosa: rebound congestion from >3 days of topical decongestant (oxymetazoline, phenylephrine) — treat by stopping decongestant, bridging with INCS ± short oral steroid taper

— Epistaxis from INCS misdirected toward septum (10% of users) — re-teach "opposite hand" technique (right hand sprays left nostril aiming laterally)

— Septal perforation rare with INCS; more common with intranasal cocaine, GPA, or surgical history

— Sedation, anticholinergic toxicity from first-generation antihistamines: falls in elderly, impaired driving (legally equivalent to alcohol impairment in some studies)

— Montelukast: neuropsychiatric effects, eosinophilic granulomatosis with polyangiitis (rare unmasking)

— Anaphylaxis from immunotherapy (SCIT > SLIT)

Board pearl: A patient using oxymetazoline for 2 weeks with worsening congestion has rhinitis medicamentosa — stop the decongestant, start an intranasal corticosteroid immediately, and consider a short oral prednisone burst (5–7 days) if mucosa severely inflamed.

Direct complications of uncontrolled allergic rhinitis:

Medication-related complications:

Functional consequences: Decreased productivity, missed work/school days, impaired learning, depression, diminished QoL — Step 3 may quantify these as justifications for therapy escalation

When to Escalate Care — Referral and Specialist Input

— Symptoms inadequately controlled despite optimized therapy (INCS + intranasal antihistamine, adherence confirmed)

— Need for specific allergen identification to guide environmental control

— Candidate for allergen immunotherapy (SCIT or SLIT)

— Diagnostic uncertainty (suspected local allergic rhinitis, mixed rhinitis)

— Concurrent moderate-to-severe asthma, especially difficult to control

— Suspected aspirin-exacerbated respiratory disease (AERD)

— Adverse reactions to multiple medications

— Pediatric patients with frequent missed school or severe atopic march

— Unilateral symptoms, masses, or bloody discharge — rule out neoplasm, foreign body

— Nasal polyps requiring evaluation/management

— Anatomic obstruction (septal deviation, turbinate hypertrophy) being considered for surgery

— Recurrent acute sinusitis or chronic rhinosinusitis refractory to medical therapy

— Suspected CSF rhinorrhea (clear unilateral discharge, β2-transferrin testing)

— Pediatric adenoid hypertrophy with sleep-disordered breathing

— Anaphylaxis during immunotherapy or new food/drug exposure

— Acute angioedema with airway involvement

— Severe epistaxis uncontrolled with pressure

— Periorbital cellulitis, vision changes, severe headache, or altered mental status with sinus symptoms — concern for orbital/intracranial extension of sinusitis

CCS pearl: On a CCS case, a patient with allergic rhinitis presenting with fever, periorbital swelling, proptosis, and ophthalmoplegia — move to ED, order CT orbits/sinuses with contrast, blood cultures, CBC, start IV vancomycin + ceftriaxone, and consult ENT and ophthalmology for possible orbital cellulitis or cavernous sinus thrombosis.

Refer to allergist/immunologist when:

Refer to ENT when:

Refer to pulmonology when: Concurrent uncontrolled asthma, suspected non-asthmatic eosinophilic bronchitis, or chronic cough workup

Refer to ophthalmology when: Vision changes, suspected keratoconus, or refractory allergic conjunctivitis with corneal involvement

Urgent evaluation (ED or same-day):

Inpatient admission rare for isolated allergic rhinitis; reserved for severe complications

Key Differentials — Other Rhinitis Subtypes

— Vasomotor (idiopathic) rhinitis: triggered by weather changes, temperature, strong odors, alcohol, spicy food; rhinorrhea/congestion dominate; no itching, no sneezing fits, no ocular symptoms; treat with intranasal corticosteroid + intranasal azelastine, ipratropium for rhinorrhea

— Gustatory rhinitis: profuse watery rhinorrhea immediately after eating (especially hot/spicy foods); intranasal ipratropium 30 min before meals

— NARES (non-allergic rhinitis with eosinophilia syndrome): clinically resembles allergic rhinitis but negative allergen testing; nasal smear shows eosinophils; responds to INCS; may evolve into AERD

— Atrophic rhinitis: elderly, post-surgical, or post-radiation; dry, crusted, foul-smelling nasal cavity with paradoxical "open nose" sensation; treat with saline irrigation, emollients

— Drug-induced rhinitis: ACE inhibitors, alpha-blockers (terazosin, doxazosin), beta-blockers, NSAIDs, sildenafil/PDE5 inhibitors, oral contraceptives, antipsychotics, cocaine; rhinitis medicamentosa from topical decongestants

— Hormonal rhinitis: pregnancy rhinitis (last trimester, resolves postpartum), hypothyroidism, menstrual cycle

— Occupational rhinitis: bakers (flour), latex (healthcare), woodworkers, lab animal handlers, chemical exposures — symptoms improve away from workplace

Key distinction: Itching, sneezing fits, and ocular symptoms strongly favor allergic rhinitis. Pure congestion/rhinorrhea without these triggered by weather, smells, or foods favors non-allergic vasomotor rhinitis — both respond to INCS, but the workup, prognosis, and immunotherapy candidacy differ.

Non-allergic rhinitis (NAR) — multiple subtypes, all with negative IgE testing:

Mixed rhinitis: allergic + non-allergic features; ~50% of clinical rhinitis is mixed — explains partial response to allergy-targeted therapy

Infectious rhinitis: viral URI (rhinovirus, coronavirus, RSV) — self-limited, systemic symptoms, fever; acute bacterial sinusitis if symptoms persist >10 days, worsen after improvement, or severe at onset (fever ≥39°C, purulent drainage, facial pain)

Key Differentials — Beyond Rhinitis

— Septal deviation: persistent unilateral or bilateral obstruction without inflammation; cure is surgical (septoplasty)

— Nasal polyps: pale grape-like masses; bilateral suggests CRSwNP, AERD, or cystic fibrosis (in children); unilateral polyp = workup for inverted papilloma or malignancy

— Adenoid hypertrophy: pediatric mouth breathing, snoring, OSA, recurrent otitis

— Choanal atresia/stenosis: congenital, neonatal respiratory distress

— Foreign body: unilateral, foul-smelling, purulent or bloody discharge in a young child — classic Step 3 stem

— Unilateral nasal obstruction, epistaxis, facial pain, cranial neuropathy, lymphadenopathy

— Squamous cell carcinoma, esthesioneuroblastoma, nasopharyngeal carcinoma (EBV-associated, Southeast Asian descent), inverted papilloma, sinonasal melanoma

— Juvenile nasopharyngeal angiofibroma: adolescent male with recurrent epistaxis and unilateral obstruction

— Granulomatosis with polyangiitis (GPA): nasal crusting, septal perforation, saddle nose, sinusitis, plus pulmonary and renal involvement; check c-ANCA/PR3

— Sarcoidosis: nasal mucosal granulomas, "strawberry skin" appearance

— IgG4-related disease: mass-like sinonasal lesions

— Eosinophilic granulomatosis with polyangiitis (EGPA): asthma + eosinophilia + sinusitis + vasculitis

— Hypothyroidism: nasal congestion plus systemic features

— Cocaine use: septal perforation, recurrent epistaxis, rhinorrhea

Board pearl: Unilateral nasal symptoms — especially with epistaxis, foul odor, or cranial nerve involvement — are never allergic rhinitis until proven otherwise. Order CT sinus with contrast and refer to ENT promptly.

Structural/anatomic causes:

Neoplastic causes — red flags warranting CT and ENT referral:

Inflammatory/systemic causes:

CSF rhinorrhea: clear, watery, unilateral discharge after trauma or surgery; β2-transferrin confirms; risk of meningitis

Vasomotor mimics:

Long-Term Plan and Secondary Prevention

— Daily INCS during predicted symptomatic periods; for perennial allergens, year-round use is appropriate

— Start INCS 2 weeks before anticipated seasonal allergen exposure (e.g., late March for tree pollen) for maximal effect at peak season

— Step down to lowest effective regimen during remission; re-escalate at first symptom return

— Dust mite: mattress and pillow encasings, weekly hot-water washing of bedding (≥130°F), reduce indoor humidity to 30–50%, remove bedroom carpeting, HEPA filtration

— Pet allergens: ideal removal; if not possible, exclude from bedroom, weekly pet bathing, HEPA filters, hardwood floors

— Pollen: check daily counts, close windows during high counts, shower and change clothes after outdoor activity, use AC instead of open windows

— Mold: repair leaks, ventilate bathrooms, dehumidify damp basements

— Tobacco smoke: counsel cessation; eliminate secondhand exposure

— Asthma: ensure controller therapy optimized; treating allergic rhinitis improves asthma control and reduces exacerbations

— Atopic dermatitis: moisturizers, topical anti-inflammatories

— OSA: screen with STOP-BANG; address nasal obstruction as part of OSA optimization

— Allergic conjunctivitis: topical olopatadine or ketotifen drops

Step 3 management: Document allergic rhinitis as a chronic problem in the problem list; review the regimen at every visit, especially before allergy seasons; reconcile against any new medications that could trigger drug-induced rhinitis.

Sustained therapy framework:

Environmental control reinforcement:

Comorbidity management:

Immunotherapy as disease modification: Consider for sustained remission; 3–5 year course with persistent benefit after discontinuation

Vaccination counseling: Annual influenza vaccine (especially with asthma); pneumococcal and COVID per age/risk; emphasize that egg allergy is not a contraindication to influenza vaccine

Adherence support: Pillbox alarms, smartphone reminders, linking INCS use to morning routine (toothbrush adjacent); written allergy action plan

Follow-Up, Monitoring, and Counseling

— 2–4 weeks after initiating or changing INCS to assess response (full benefit takes 2 weeks)

— 3 months for stable patients on chronic therapy

— Annual review for those well-controlled; pre-seasonal visit for seasonal patients

— Sooner if new symptoms, exacerbation, or medication side effects

— Total Nasal Symptom Score (TNSS): rates congestion, rhinorrhea, sneezing, itching 0–3 each

— Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for functional impact

— Patient symptom diary correlated with pollen counts

— Children on chronic INCS: annual height/weight, growth velocity plotting

— Anyone on INCS: nasal exam for crusting, septal integrity, epistaxis; review spray technique

— Pseudoephedrine users: BP at each visit; discontinue if HTN worsens

— Montelukast users: screen for mood changes, sleep disturbance, behavioral changes at every visit; document discussion

— Immunotherapy patients: symptom diary, asthma control, post-injection reactions

— Shake bottle, prime if new or unused >1 week

— Tilt head slightly forward, not back

— Use opposite hand (left hand for right nostril) and aim laterally toward outer ear, away from septum

— Gentle sniff, not a deep snort

— Avoid blowing nose for 15 minutes after

— "Controller, not rescue" framing for INCS

— Expected timeline of effect

— Realistic environmental control goals

— When to call: persistent symptoms despite adherence, unilateral symptoms, epistaxis, vision changes, fever

Board pearl: "INCS isn't working" in 80%+ of cases comes down to inadequate duration, poor technique, or non-adherence, not pharmacologic failure — re-educate before escalating therapy.

Follow-up cadence:

Symptom tracking tools:

Monitoring parameters:

Spray technique counseling (the single most missed intervention):

Patient education themes:

Coordination: Share plan with asthma management team; communicate with school nurse for pediatric patients

Ethical, Legal, and Patient Safety Considerations

— SCIT and SLIT carry anaphylaxis risk — written informed consent should specify risks of systemic reaction, time commitment (3–5 years), and need for adherence

— First SLIT dose given under observation in the office; subsequent home doses require patient to fill epinephrine auto-injector prescription and demonstrate use

— SCIT requires 30-minute observation post-injection at every visit — patient leaving early is a documented safety risk

— Document discussion of neuropsychiatric side effects (depression, anxiety, sleep disturbance, suicidal ideation) before prescribing

— Particularly important in adolescents and patients with underlying mood disorders

— Provide written safety information; share decision-making with parents for pediatric patients

— Engage older children in decisions about chronic medications and immunotherapy

— Address school accommodation under Section 504 or IEP when symptoms impair learning

— First-generation antihistamines impair driving comparably to alcohol intoxication; relevant for commercial drivers (CDL), pilots, machinery operators

— Counsel patients to avoid these agents if safety-sensitive occupations

— Workers' compensation documentation when occupational exposure causes or worsens rhinitis

— OSHA reporting may apply for certain workplace exposures

— When transferring care, communicate active immunotherapy regimen including allergen extract, current dose/phase, and recent reactions — interruptions of >4 weeks require dose reduction to avoid reaction

— Discharge from pediatric to adult care: ensure continuity of INCS, immunotherapy, and asthma action plan

Step 3 management: Before prescribing montelukast, document a shared decision-making discussion of neuropsychiatric risks, especially in adolescents — failure to do so is both a clinical safety and medicolegal concern.

Informed consent for immunotherapy:

Montelukast and FDA boxed warning (2020):

Pediatric assent and parental consent:

Driving and occupational safety:

Occupational rhinitis reporting:

Transitions of care (Step 3 favorite):

Health equity: Disparities in indoor allergen burden (cockroach, mouse, mold) in lower-income housing — connect families to housing remediation resources

Pharmacy safety: Reconcile OTC INCS and antihistamines that patients often don't disclose; check for duplicative therapy and pseudoephedrine purchases (logged under federal law)

High-Yield Associations and Rapid-Fire Facts

Board pearl: When a Step 3 question gives you a stem with "moderate-to-severe persistent symptoms" + adequate trial of oral antihistamine + impaired sleep — the answer is start daily intranasal corticosteroid, not "add a second oral agent."

Atopic march sequence: atopic dermatitis (infancy) → food allergy → asthma → allergic rhinitis (childhood/adolescence)

"One airway" hypothesis: Allergic rhinitis and asthma are manifestations of the same inflammatory process — treating rhinitis improves asthma control

Samter's triad / AERD: asthma + nasal polyps + aspirin/NSAID sensitivity — avoid all COX-1 inhibitors; consider aspirin desensitization

Pale boggy turbinates with clear discharge = allergic; erythematous with purulent = infectious; pale dry crusted = atrophic

Unilateral nasal symptoms = workup for foreign body (child), tumor (adult), CSF leak (post-trauma), or polyp

Bloody, crusting, septal perforation, saddle nose = think GPA — order c-ANCA/PR3

Saddle nose deformity differential: GPA, congenital syphilis, relapsing polychondritis, cocaine, trauma

Allergic shiners, Dennie-Morgan lines, allergic salute = pediatric atopic stigmata

Cobblestoning of posterior pharynx = chronic postnasal drip

Cetirizine = most sedating of second-generation antihistamines; fexofenadine = least sedating

Avoid first-generation antihistamines in elderly (Beers) and children <6 (excitation/sedation)

INCS takes 2 weeks for full effect — counsel adherence

Hold antihistamines 5–7 days before skin prick testing (TCAs 7–14 days)

Mometasone and fluticasone furoate have least growth impact in pediatric long-term INCS

Budesonide: safest INCS in pregnancy

Loratadine, cetirizine: preferred oral antihistamines in pregnancy

Avoid pseudoephedrine in T1 (gastroschisis association)

Oxymetazoline ≤3 days only to prevent rhinitis medicamentosa

Ipratropium nasal spray: best for rhinorrhea-predominant and gustatory rhinitis

Montelukast: FDA boxed warning for neuropsychiatric effects

SCIT: 30-min post-injection observation; epinephrine on-site; relative contraindication with beta-blockers

SLIT: prescribe epinephrine auto-injector; first dose in-office

β2-transferrin: confirms CSF rhinorrhea

Local allergic rhinitis: classic symptoms with negative SPT/IgE; nasal provocation diagnostic

Board Question Stem Patterns

Step 3 management: Step 3 favors specific, named first-line therapies — name the drug (fluticasone, budesonide), specify duration of trial (2 weeks), and identify a follow-up interval (2–4 weeks) in your reasoning.

Stem 1 — "Failed oral antihistamine": 28-year-old with year-round sneezing, rhinorrhea, congestion despite daily loratadine for 1 month, sleep impaired. Exam: pale boggy turbinates. → Start intranasal fluticasone daily, counsel 2-week onset

Stem 2 — "Recurrent sinusitis on multiple antibiotics": Patient on 4th antibiotic course for "sinus infection" in a year, no fever, clear discharge, postnasal drip → diagnosis is allergic rhinitis; treat with INCS, not antibiotics

Stem 3 — Pregnancy: 26-year-old at 16 weeks gestation with seasonal allergic rhinitis. → Saline irrigation + intranasal budesonide; avoid pseudoephedrine in T1

Stem 4 — Elderly with new "allergy": 72-year-old started lisinopril 2 months ago, now with chronic congestion. → Drug-induced rhinitis; switch antihypertensive or trial INCS

Stem 5 — Rhinitis medicamentosa: Patient using oxymetazoline daily for 3 weeks with worsening congestion → Stop decongestant, start INCS, consider short oral steroid burst

Stem 6 — Unilateral symptoms: 65-year-old smoker with unilateral nasal obstruction and epistaxis × 3 months → CT sinus with contrast and ENT referral, not antihistamines

Stem 7 — Pediatric: 6-year-old with mouth breathing, allergic shiners, snoring, school difficulty → Intranasal mometasone daily (approved age ≥2) + environmental control; screen for OSA

Stem 8 — AERD: Adult with asthma exacerbation after taking ibuprofen, history of nasal polyps → diagnosis aspirin-exacerbated respiratory disease; avoid all NSAIDs, consider aspirin desensitization

Stem 9 — Immunotherapy candidacy: Patient maximally treated, still symptomatic, wants long-term solution → Refer for allergen immunotherapy

Stem 10 — Occupational: Baker with workday-only symptoms resolving on weekends → Specific IgE to flour antigens, workers' comp documentation

Stem 11 — GPA mimic: Chronic nasal crusting, septal perforation, hematuria → c-ANCA/PR3, urinalysis, refer to rheumatology

Stem 12 — Foreign body: 3-year-old with unilateral foul-smelling purulent discharge → ENT for foreign body removal

One-Line Recap

Allergic rhinitis is an IgE-mediated nasal mucosal inflammation best managed in the outpatient setting with environmental control plus daily intranasal corticosteroid as first-line for moderate-to-severe persistent symptoms, escalating to combination intranasal therapy and ultimately allergen immunotherapy for refractory disease.

— Diagnose clinically (itching + sneezing + watery rhinorrhea + congestion + ocular symptoms with pale boggy turbinates); reserve specific IgE/SPT for treatment failure or immunotherapy planning

— First-line for mild intermittent: second-generation oral antihistamine PRN; first-line for moderate–severe or persistent: daily INCS with 2-week trial before judging efficacy

— Step up to combination INCS + intranasal antihistamine (azelastine/fluticasone) before adding oral agents; refer for immunotherapy when adequately optimized regimens still fail or when allergic asthma coexists — it is the only disease-modifying therapy

— Special populations: budesonide and loratadine/cetirizine preferred in pregnancy; avoid first-generation antihistamines in elderly (Beers) and oral decongestants in HTN/CAD/BPH; monitor growth in pediatric chronic INCS users; document montelukast neuropsychiatric risk discussion

— Red flags away from allergic rhinitis: unilateral symptoms, epistaxis, septal perforation, saddle nose, cranial neuropathy → CT sinus and ENT/rheumatology referral; consider GPA, neoplasm, foreign body, or CSF leak

Board pearl: The Step 3 winning move is almost always "start daily intranasal corticosteroid, counsel on 2-week onset and proper technique, reassess in 2–4 weeks" — and to think of allergic rhinitis as one component of a unified atopic airway alongside asthma, conjunctivitis, and atopic dermatitis that responds best to a longitudinal, environmental-plus-pharmacologic plan rather than episodic symptom-only treatment.

High-yield recap bullets: